Clinical trial
Immune Response in Subjects With Fabry Disease Who Are Switching From Agalsidase Alfa to Agalsidase Beta
NCT01745185 is registered in ClinicalTrials.gov with O & O Alpan LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Immune Response in Subjects With Fabry Disease Who Are Switching From Agalsidase Alfa to Agalsidase Beta
- Lead sponsor
- O & O Alpan LLC
- Phase
- Observational
- Overall status
- Completed
- Start date
- June 30, 2012
- Completion date
- August 7, 2016
- Enrollment
- 30 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.